Wockhardt Limited's Zaynich antibiotic shows over 97% efficacy against carbapenem-resistant bacteria, impacting global ...

Mumbai: Wockhardt has announced that Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 percent clinical efficacy ...

Shares of Wockhardt were in high demand on Monday after the company said that its drug Zaynich has achieved over 97 per cent ...

Time is morbidity and mortality (and money), and guidelines recommend sepsis screening on the hospital wards. Two studies ...

Indian benchmark indices opened in the red, reflecting a negative start to the trading week. However, one stock bucked the ...

The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...

Royal College of Physicians (1991) 1991–2000 Aggressive treatment, prophylaxis and investigation of all children aged <7 years [81] American Academy of Pediatrics Guideline (1999) Aggressive ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Its lead combination - cefepime-taniborbactam – is being developed in phase 3 trials for complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia, and ventilator ...